Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs GeoVax Labs (GOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GeoVax Labs is the larger company by market cap ($985,459 vs $982,950), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | GOVX |
|---|---|---|
| Share price | $1.88 | $1.81 |
| Market cap | $982.95K | $985.46K |
| 1-day change | -3.85% | -5.24% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $509.89 | $-15.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.49M |
| Revenue growth (YoY) | — | -37.06% |
| Net income (latest FY) | — | $-21.46M |
| Operating margin | — | -869.34% |
| Net margin | — | -862.34% |
| 52-week high | $357.60 | $270.60 |
| 52-week low | $1.85 | $1.51 |
| Distance from 52-week high | -99.48% | -99.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +375.20% | +452.49% |
| Average volume | 618.91K | 213.41K |
| Shares outstanding | 524.24K | 544.45K |
| Employees | 11 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
BDRX vs GOVX FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or GeoVax Labs?
GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $982.95K for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Are Biodexa Pharmaceuticals American Depositary Shs and GeoVax Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.